Navigation Links
Horizon Therapeutics Announces Senior Management Appointments
Date:1/6/2009

SKOKIE, Ill., Jan. 6 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Amy Grahn to vice president, clinical operations and Iain Duncan to senior vice president of operations.

"Amy and Iain bring valuable operations experience that is vital as we prepare regulatory filings in the U.S. and Europe and move forward with the anticipated commercialization of our lead product candidate, HZT-501," said Timothy P. Walbert, president and chief executive officer. "During their respective careers, Amy and Iain have been instrumental in the growth of start-up as well as established biotech and pharmaceutical companies and their leadership will be an important part of Horizon's future growth."

Ms. Grahn has more than 20 years pharmaceutical industry experience spanning pre-clinical research to sales, with a primary focus on clinical operations. Ms. Grahn was most recently vice president of clinical operations at MedGenesis Therapeutix Inc. in British Columbia, Canada where she was responsible for strategic planning, development and implementation of clinical and pre-clinical development plans for therapeutic agents delivered via the MedGenesis convection-enhanced delivery (CED) platform.

During her career, Ms. Grahn has held various senior level positions at Neopharm, Inc., Takeda Pharmaceuticals North America, Inc., G.D. Searle & Company and Abbott Laboratories.

At Horizon, Ms. Grahn will lead all clinical operations activities. Ms. Grahn has a master's degree in biochemistry from Illinois Institute of Technology in Chicago and a bachelor's degree in chemistry and biology from Knox College in Galesburg, Ill.

Mr. Duncan has more than 20 years executive-level management experience in international, general and operations management. Mr. Duncan was a co-founder of Corus Pharma, Inc., which was purchased by Gilead Sciences, Inc. and was most recently vice president of operations at Corus where he was integral in the development and manufacturing of aztreonam lysinate for inhalation (AI). Additionally, he supervised the formulation and development of three additional drug candidates.

Prior to Corus, Mr. Duncan held positions at Pathogenesis Inc. and Lyondell Chemical.

At Horizon, Mr. Duncan will lead all manufacturing, quality control and supply chain activities. Mr. Duncan has a bachelor's degree in biology from Trent University in Ontario, Canada.

The Company recently announced that its lead product HZT-501 met the primary endpoints in two Phase 3 clinical studies, REDUCE-1 and REDUCE-2 (The Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study). In REDUCE-1, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric ulcers versus treatment with ibuprofen alone. In REDUCE-2, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric and/or duodenal ulcers versus treatment with ibuprofen alone.

The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) and based on the results the Company plans to submit filings to U.S. and European regulatory authorities in 2009.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
2. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
3. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
4. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
5. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
9. BioHorizons Announces Agreement to Purchase Implant Logic Systems
10. Out beyond the horizon
11. Out beyond the horizon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):